Product Details

Verlora is a sterile injectable formulation that meets British Pharmacopoeia (BP) standards. Specifically, it delivers Lorazepam IP for use as an intermediate-acting benzodiazepine through the intramuscular (I.M.) or intravenous (I.V.) route. As a result, it offers reliable sedation, anxiolysis, and anticonvulsant action for a range of clinical settings.

The injection contains:

• Lorazepam IP (as Lorazepam) – An intermediate-acting benzodiazepine that enhances GABA-A receptor activity in the central nervous system. Consequently, it produces sedation, anxiolysis, muscle relaxation, and anticonvulsant effects with a comparatively stable duration of action.

Physicians use Verlora for the management of status epilepticus, procedural sedation, and premedication before anaesthesia or surgical procedures. In addition, its dual-route (I.M./I.V.) formulation allows flexible administration based on clinical urgency. Because of this profile, Verlora suits hospitals, ICUs, and emergency departments where prompt sedative or anticonvulsant intervention is required.

Key Features:

• Overall, this BP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the dual-route (I.M./I.V.) formulation offers flexible clinical use
• Furthermore, each vial delivers precise, validated dosage accuracy
• Notably, rigorous purity and sterility testing backs every stage of manufacturing
• Beyond that, light-protected vial packaging preserves product stability during storage
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, ICUs, and emergency care units